Phase 3
N=136
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
Idiopathic Pulmonary Arterial Hypertension · Cardiomyopathy
Bottom Line
View on ClinicalTrials.gov: NCT00626028 ↗Enrolled (actual)
136
Serious AEs
2.5%
Results posted
Sep 2010
Primary outcome: Primary: Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity) — 28; 16 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Nitric Oxide for inhalation (Drug); Oxygen (Drug); Nitric Oxide plus Oxygen (Drug)
- Age
- Pediatric, Adult · 0+ yrs
- Sex
- All
- Sponsor
- Mallinckrodt
- Primary completion
- Feb 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity) |
28; 16 | — |
| SECONDARY Number of Participants With Related Surgical Procedures Within 1 Year |
44; 21 | — |
| SECONDARY Number of Participants With Adverse Events (AEs) |
5; 2 | — |
| SECONDARY Number of Participants With Serious Adverse Events (SAEs) |
3; 0 | — |
| SECONDARY Number of Participants With Related Surgical Procedures Within 3 Years |
12; 6 | — |
Summary
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
Eligibility Criteria
Inclusion Criteria
- Must have any one of these three disease categories:
- Idiopathic Pulmonary Arterial Hypertension
- Mean pulmonary arterial pressure (PAPm) > 25 millimeters of mercury (mmHg) at rest, pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and PVRI> 3 u•m^2 or diagnosed clinically with no previous catheterization
- Congenital heart disease (CHD) with pulmonary hypertension repaired and unrepaired
- PAPm > 25 mmHg at rest and PVRI> 3 u•m^2 or diagnosed clinically with no previous catheterization
- Cardiomyopathy
- PAPm > 25 mmHg at rest and Pulmonary vascular resistance index (PVRI)> 3 u•m^2 or diagnosed clinically with no previous catheterization
- Scheduled to undergo right heart catheterization to assess pulmonary vasoreactivity by acute pulmonary vasodilation testing.
- Male or female, ages 4 weeks to 18 years, inclusive
- Signed informed consent/assent
Exclusion Criteria
- Focal pulmonary infiltrates on chest radiograph.
- Diagnosed with severe obstructive or restrictive pulmonary disease that is significantly contributing to the patient's pulmonary hypertension.
- Received treatment with nitric oxide for inhalation within 30 days prior to study initiation, are on other investigational medications, nitroglycerin, sodium nitroprusside, sildenafil, other Phosphodiesterase type 5 (PDE-5) inhibitors, or prostacyclin
- Pregnant [urine human chorionic gonadotropin positive (HCG +)]
- Baseline Pulmonary capillary wedge pressure (PCWP) > 20 mmHg
Data sourced from ClinicalTrials.gov (NCT00626028). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.